Navigation Links
Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
Date:9/5/2013

LAUSANNE, Switzerland and SAN FRANCISCO, September 5, 2013 /PRNewswire/ --

Go To Market Consulting Inc. (Go To Market), a San Francisco headquartered business development representation and marketing services life sciences consulting firm, and Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, have entered into an alliance to identify and scout West Coast companies, research institutes and/or individual investigators with in-licensing opportunities, including new compounds, products and/or technologies in oncology, auto-immune, infectious disease and metabolic conditions. Go To Market will collaborate with Debiopharm's existing in-house scouting team for first in-class opportunities for small molecule, antibody and peptide based product candidates.

In recognition of the depth and breadth of life science innovation in the West and in particular, the San Francisco Bay area, known for its culture of innovation, Debiopharm has selected Go To Market to strengthen its local activity in the region. Go To Market will work with Debiopharm's experienced scouting team to further increase the company's accessibility to in-licensing opportunities. David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: "We have selected Go To Market because of their strength and understanding in the life sciences product development area. Their successful presence on the West Coast is a major asset to our search for new molecules. With this partnership we are deepening our commitment to finding the most promising drugs to develop for patients."

Maria Chiam, Founder of Go To Market added: "the West Coast is a rich area in science innovation. Debiopharm's track record of investing into and collaborating with early stage biopharmaceutical programs make it a choice partner for researchers and organizations wanting to move their preclinical programs into clinical development. Go To Market Consulting is delighted to work with Debiopharm to bring next generation therapeutics and diagnostic and personalized medicine initiatives to the market."

About Go To Market Consulting Inc.

Go To Market focuses on developing B2B partnerships and end-customer relationships to create and grow leads and sales opportunities for companies in the biotechnology, pharmaceutical and device area. Go to Market has a combination of deep industry knowledge and international strategic, technical and commercial capabilities in life sciences. For more information on Go To Market Consulting Inc., please visit: http://www.go2mc.com

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm International SA Contact
Beatrice Hirt
Communication Coordinator
beatrice.hirt@debiopharm.com
Tel.: +41(0)21-321-01-11    

Additional Media Contacts
In London
Maitland
Brian Hudspith
bhudspith@maitland.co.uk
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
martina.schwarzkopf@russopartnersllc.com
Tel: +1-212-845-4292


Go To Market Contact
In San Francisco
Maria Chiam
Founder
Maria.chiam@go2mc.com
Tel :+1-415-606-5839



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Cardiac Rhythm Management (CRM) Devices - Market Growth Analysis, 2009-2015
2. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
3. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. European Clot Management Device Market To Exceed $170 Million By 2022
5. AVTs Customer Medbox, Makes Wall Street Journal MarketWatch Headlines Again
6. South East Asia Medical Device Market Reports
7. Advances in Magnetic Resonance Imaging (MRI) Market (2013-2018) -- Technology Trend Analysis -- By Architecture, Field Strengths, Technology & Applications in Medical Diagnostics with Market Landscape Analysis -- Estimates up to 2018
8. World Pain Relieving Drug Market 2013-2023
9. Orphan Drugs for Cancer: R&D and Market 2013-2023
10. Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023
11. CIVETS Medical Device Market Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):